Top Links

Articles Related to Ovarian cancer

Former Effective Immunotherapy without Adverse Events of Inoperable Epithelial Ovarian Cancers and a Prospect for the Immune Prophylaxis

Current cancer treatments by immune checkpoint blockades are limited due to severe adverse events caused by alteration of the immune system required for homeostasis of normal tissues. Common cancer chemotherapy alters the quality of patients’ lives. Platinum-based treatment can lead to severe neurotoxicity with chronic debilitation. Additionally, survival of patients with epithelial ovarian cancers (EOCs) has remained poor despite extensive cytoreductive surgery, high dose chemotherapy, checkpoint blockades and immunotherapies effective in some other types of cancer. The pathobiology of EOC cancer stem cells (CSCs) is not well understood. Observations demonstrate that EOCs exhibit in vivo two distinct CSC types - perivascular diploid CSCs dividing asymmetrically with the help of the host suicidal CD8+ T cells, and haploid CSCs at the cancer abdominal surface originating from meiosis I cytokinesis of bulk surface cancer cells. The perivascular CSCs contribute to the cancer cell bulk and, via left ovary venous blood, can cause EOC liver metastases. Haploid CSCs released from the bulk cancer surface cause the common pelvic and abdominal EOC spread. Former elimination of the host antibodies blocking T cell effectors by intermittent doses of cyclophosphamide exhibiting significant immunomodulatory anticancer effects, facilitation of the immune system reactivity against alloantigens of cancer cells by blood transfusions, and augmentation of anticancer immunity by bacterial toxins, resulted during the subsequent treatment-free period into rejection of inoperable EOCs without any adverse events during the treatnment. To help prevent cancer relapses, patients treated for advanced primary epithelial cancers should be considered as candidates for continuously stimulating immune anticancer activity by treatments such as daily metformin and weekly lentinan consumptions.
View complete article: PDF  |  Full-text

Immune Checkpoint and Ovarian Cancer

Many scientists and biotechnology companies had given up on the idea of cancer immunotherapy in 1990s. Almost a decade after first detection of T cell suppression effect of CTLA4 the identity of its antibody was established. While they are found effective in many cancers including melanoma, lung cancer etc. immune checkpoint inhibitors have lent an important measure to manage recurrent and refractory ovarian cancer. This subject needs constant updating specially for students of ovarian cancer who are looking at this avenue of cure with much hope.
View complete article: PDF  |  Full-text

Increased High Mobility Group Protein A2/SMAD3 Relates to Ovarian Cancer Progression

The high mortality associated with ovarian cancer is generally related to the development of drug-resistant disease. HMGA2 protein, a member of the high-mobility group AT-hook (HMGA) family of non-histone chromatin binding factors, is overexpressed in high-grade serous ovarian and tubal carcinomas, though little is known about its contribution to disease progression and drug resistance. We sought to assess whether compositional changes in HMGA2 production were associated with ovarian cancer progression.
View complete article: PDF  |  Full-text

Molecular Mechanism Linking BRCA1 Dysfunction to High Grade Serous Epithelial Ovarian Cancers with Peritoneal Permeability and Ascites

Ovarian cancer constitutes the second most common gynecological cancer with a five-year survival rate of 40%. Among the various histotypes associated with hereditary ovarian cancer, high-grade serous epithelial ovarian carcinoma (HGSEOC) is the most predominant and women with inherited mutations in BRCA1 have a lifetime risk of 40-60%. HGSEOC is a challenge for clinical oncologists, due to late presentation of patient, diagnosis and high rate of relapse. Ovarian tumors have a wide range of clinical presentations including development of ascites as a result of deregulated endothelial function thereby causing increased vascular permeability of peritoneal vessels.
View complete article: PDF  |  Full-text

Molecular Mechanisms of Mismatch Repair Genes in Cancer – A Brief Review

The DNA mismatch repair (MMR) system is necessary for the maintenance of genomic stability. The MMR system promotes genomic fidelity by repairing base-base mismatches, insertion-deletion loops (IDLs) and heterologies generated during DNA replication and recombination.
View complete article: PDF  |  Full-text


Editorial Board Members Related to Ovarian cancer

Farrukh Aqil

Assistant professor
Department of medicine
University of louisville
United States

PATRICIA A. KRUK

Professor
Department of Obstetrics and Gynecology
USF Morsani College of Medicine
University of South Florida
United States

RICHARD G. MOORE

Professor
Department of Obstetrics and Gynecology
Warren Alpert Medical School
Brown University
United States

JONG SUP PARK

Professor
Department of Obstetrics and Gynecology
Seoul St. Mary’s Hospital
Catholic University Medical College
Korea
Submit Manuscript